Context-dependent CpG methylation directs cell-specific binding of transcription factor ZBTB38

Epigenetics. 2022 Dec;17(13):2122-2143. doi: 10.1080/15592294.2022.2111135. Epub 2022 Aug 24.

Abstract

DNA methylation on CpGs regulates transcription in mammals, both by decreasing the binding of methylation-repelled factors and by increasing the binding of methylation-attracted factors. Among the latter, zinc finger proteins have the potential to bind methylated CpGs in a sequence-specific context. The protein ZBTB38 is unique in that it has two independent sets of zinc fingers, which recognize two different methylated consensus sequences in vitro. Here, we identify the binding sites of ZBTB38 in a human cell line, and show that they contain the two methylated consensus sequences identified in vitro. In addition, we show that the distribution of ZBTB38 sites is highly unusual: while 10% of the ZBTB38 sites are also bound by CTCF, the other 90% of sites reside in closed chromatin and are not bound by any of the other factors mapped in our model cell line. Finally, a third of ZBTB38 sites are found upstream of long and active CpG islands. Our work therefore validates ZBTB38 as a methyl-DNA binder in vivo and identifies its unique distribution in the genome.

Keywords: Alu repeats; DNA methylation; E2F factor; cell cycle; zinc finger protein ZBTB38.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Binding Sites
  • CpG Islands
  • DNA Methylation*
  • Gene Expression Regulation
  • Humans
  • Mammals / genetics
  • Mammals / metabolism
  • Protein Binding
  • Repressor Proteins / genetics
  • Repressor Proteins / metabolism
  • Transcription Factors* / genetics
  • Transcription Factors* / metabolism
  • Zinc Fingers

Substances

  • Transcription Factors
  • ZBTB38 protein, human
  • Repressor Proteins

Grants and funding

This work was supported by the Fondation ARC pour la Recherche sur le Cancer [PGA1/RF20180206807]; Fondation pour la Recherche Médicale [FDT20150532354]; Ligue contre le cancer Comité de Paris [RS11/75-8; RS12/75/95-21; RS13/75-59]; Association pour la Recherche sur les Tumeurs de Prostate [RAK22004KKA]; Labex ‘Who am I?’ [ANR-11-LABX-0071 and ANR-11-IDEX-005-02]; Agence Nationale de la Recherche [PRCI INTEGER ANR-19-CE12-0030-01]; Electricité de France [RB2018-14]; FP7 Marie Curie action grant [PIRG07-GA-2010-268448].